// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

The impact of maintenance lenalidomide and depth of response on the mutational status of the myeloma clone from presentation to relapse

J Jones - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Lenalidomide

Role of FISH in relapsed myeloma

LJ Nallathambi - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

TP53

Review of an eight colour flow cytometry panel in the diagnosis of multiple myeloma

V Pyc - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Lanthanum carbonate

Cancer network level analysis of clinical outcomes in transplant ineligible NDMM patients

F Djebbari - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Thalidomide

Hepatitis B screening and reactivation in patients receiving rituximab for diffuse large B cell lymphoma

NLB Muhamad - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Alkaline phosphatase

Long‐term follow‐up with GS‐4059, a selective irreversible BTK inhibitor, in patients with relapsed and refractory chronic lymphocytic leukemia

HS Walter - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

N/A

L-Tyrosine

Double‐hit lymphoma frontline therapy and consolidation – a ten year retrospective case study review of patients with double‐hit lymphoma in the Northern Region of England

M Lannon - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Bendamustine

Feasibility of administration of ofatumumab infusions in patients unable to tolerate rituximab

L Chen - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

N/A

ofatumumab Intravenous

Allogeneic stem cell transplantation in patients with Hodgkin Lymphoma – a retrospective single centre case series

N Lafferty - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Adcetris

Piloting service provision of microarray‐based genomic profiling to detect chromosomal abnormalities in chronic lymphocytic leukemia

M Timmins - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

TP53

Is overall survival and event free survival comparable between recently introduced GDP salvage chemotherapy compared to IVE and DHAP chemotherapy? A retrospective review of relapsed and refractory lymphoma patients in the northern region of England

L Dunning - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Dexamethasone

Hands‐on district general hospital experience of rituximab‐idelalisib in a co‐morbid elderly cohort with chronic lymphocytic leukaemia

R Ayto - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Bendamustine

Preliminary results of a phase 1b dose escalation and dose expansion study of GS‐4059 in combination with idelalisib in subjects with B‐cell malignancies

MJS Dyer - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Alkaline phosphatase

Positive benefits of changing from intravenous Rituximab administration to subcutaneousadministration: a single centre experience

S Irwin - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Bendamustine

Anthracycline chemotherapy in diffuse large B cell lymphoma; myocardial damage and association with pre‐existing cardiovascular risk factors. Experience from a large DGH

T Fail - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Doxorubicin

A pilot study to minimise un‐necessary blood testing for non‐Hodgkin's lymphoma patients receiving R‐CHOP chemotherapy

R Shah - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Development of an Idelalisib safety monitoring tool

R Hinton - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Idelalisib

Bone marrow involvement by follicular lymphoma and its correlation with the initial full blood count: a retrospective study

I Saeed - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

An audit demonstrating the importance of performing echocardiograms in patients with diffuse large B‐cell lymphoma receiving R‐CHOP chemotherapy

L Winn - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Focal splenic lesions by CT or PET in the setting of B‐cell lymphoma are significantly associated with diffuse large B lymphoma histology

F Mir - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved